This is the authors' abstract. We don't add key points for this paper.
gene mutation (c.1033G>T, p.G345C) presented with 3- to 6-fold higher serum iodothyronine levels and more severe clinical manifestation than 2 other family members carrying the same mutation. The leukocytes of the proband expressed both wild-type and mutant THRB mRNAs, excluding the possibility of a partial deletion of the allele not carrying the mutation. The proband's fibroblasts showed reduced responsiveness to triiodothyronine compared with those of another affected family member. The more severe clinical and biochemical phenotype suggest a modifier-mediated worsening of the resistance to thyroid hormone.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Fujisawa et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: